Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 0.41 |
| ▸ | EGFR | P00533 | 7/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNH | P51946 | 1/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | YES1 | P07947 | 1/20 | 0.37 |
| ▸ | LYN | P07948 | 1/20 | 0.37 |
| ▸ | HCK | P08631 | 1/20 | 0.37 |
| ▸ | FGR | P09769 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | FER | P16591 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31213849 | 0.98 | BTK (0.42) | BTKEGFRKCNH2CDK7CDK9 | |
| SCHEMBL31213919 | 0.97 | BTK (0.42) | BTKEGFRKCNH2CDK7CDK9 | |
| SCHEMBL30325769 | 0.97 | BTK (0.42) | BTKEGFRKCNH2ABL1ERBB2 | |
| SCHEMBL31213922 | 0.94 | CDK7 (0.39) | BTKEGFRKCNH2CDK7CDK9 | |
| SCHEMBL31213986 | 0.93 | BTK (0.44) | BTKEGFRKCNH2ABL1ERBB2 | |
| SCHEMBL31213982 | 0.91 | BTK (0.38) | BTKEGFRKCNH2ABL1ERBB2 | |
| SCHEMBL31213870 | 0.91 | BTK (0.38) | BTKEGFRKCNH2CDK2ABL1 | |
| SCHEMBL31213890 | 0.91 | BTK (0.40) | BTKEGFRKCNH2CDK2ABL1 | |
| SCHEMBL31213924 | 0.91 | BTK (0.40) | BTKEGFRKCNH2CDK7CDK9 | |
| SCHEMBL31213877 | 0.90 | BTK (0.39) | BTKEGFRKCNH2CDK7CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2024-11-21 | — | — | US | claimed |
| EP-4405358-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H Pharmaceuticals Co., Ltd. (CN) | 2024-07-31 | — | — | EP | claimed |
| CN-118043327-A | FGFR inhibitors and methods of use thereof | 思康睿奇(上海)药业有限公司 | 2024-05-14 | — | — | CN | claimed |
| WO-2023046117-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | WO | claimed |
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| EP-4405358-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H Pharmaceuticals Co., Ltd. (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-118043327-A | FGFR inhibitors and methods of use thereof | 思康睿奇(上海)药业有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023046117-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR1, FGFR3, FGFR4 | BTK 168/4885EGFR 45/4885KCNH2 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.